Faeth Therapeutics, Inc.
FTH evidence brief
What we can confirm
- BioSniper Score:
- 8.6 / 10
- Market Cap:
- $1.01B
- Lead Asset:
- piktor (Phase 2)
What it means
What to watch
Prepared research question
What matters most for FTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · FTH
Faeth Therapeutics (FTH) is a clinical-stage oncology company developing multi-node therapies targeting tumor metabolism and signaling, with its lead program PIKTOR (serabelisib + sapanisertib) in Phase 2 for endometrial and breast cancer.
Key risk: Cash burn rate
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.01B
Cash Runway
—
Lead Asset
piktor (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates for Faeth Therapeutics, Inc..
Faeth Therapeutics (FTH) is a clinical-stage oncology company developing multi-node therapies targeting tumor metabolism and signaling, with its lead program PIKTOR (serabelisib + sapanisertib) in Phase 2 for endometrial and breast cancer.
- Lead program PIKTOR is a Phase 2 multi-node inhibitor of the PI3K/AKT/mTOR pathway for endometrial and breast cancer [pipeline].
- Cash & equivalents of $26.9M as of 2026-06-30 [sec].
- Net loss of $16.0M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $173.0M as of 2026-06-30 [sec].
- FDA granted Fast Track designation for PIKTOR (sapanisertib + serabelisib) with paclitaxel for advanced/recurrent endometrial cancer [news · published 2026-08-17].
What works
- PIKTOR has received FDA Fast Track designation for endometrial cancer, which may accelerate development and review [news · published 2026-08-17].
- The company has a diversified pipeline of conditionally active antibodies targeting VISTA, VSIG4, CD39, and a CD28 bispecific, all in Phase 1/2 [pipeline].
- A $200M private placement concurrent with the Sensei Biotherapeutics acquisition provides substantial capital to advance programs [news · published 2026-02-18].
What to weigh
- The company reported a net loss of $16.0M for the period ending 2026-06-30, indicating ongoing cash burn [sec].
- PIKTOR faces a competitive landscape including alpelisib, inavolisib, capivasertib, everolimus, and temsirolimus [pipeline].
- Multiple pipeline candidates (sns-201, sns-102, sns-103) are in early Phase 1/2 with no disclosed efficacy data, implying high technical risk [pipeline].
From the filings
Quoted directly from source documents.
PIKTOR is a multi-node PI3K/AKT/mTOR inhibitor in Phase 2 for endometrial and breast cancer.
“multi-node inhibition of the PI3K/AKT/mTOR pathway”
FDA granted Fast Track designation for PIKTOR with paclitaxel in endometrial cancer.
“Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer”
News · August 17, 2026
Risks & what to watch (3)›
Key risks
- Cash burn rate — Net loss of $16.0M in the period ending 2026-06-30; cash of $26.9M may fund operations for a limited time [sec].
- Early-stage pipeline — Most pipeline candidates (sns-201, sns-102, sns-103) are in Phase 1/2 with no disclosed efficacy data [pipeline].
- Competitive PI3K/AKT/mTOR space — PIKTOR competes with multiple approved and advanced agents like alpelisib, inavolisib, capivasertib [pipeline].
What to watch
- PIKTOR endometrial cancer data catalyst expected by year-end 2026 [news · published 2026-08-11].
- KOL event on October 6, 2026 discussing PIKTOR strategy [news · published 2026-09-08].
- Progress of early-stage pipeline candidates (sns-201, sns-102, sns-103) through Phase 1/2 [pipeline].
Sources: News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Faeth Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Faeth Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 1/Phase 2
5 candidates
No upcoming catalysts tracked
23 buys · 4 sells (180d)
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 88.5%
- Days to cover
- 19.6
- Shares short
- 834,411
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
FTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Faeth Therapeutics, Inc.?
Faeth Therapeutics (FTH) is a clinical-stage oncology company developing multi-node therapies targeting tumor metabolism and signaling, with its lead program PIKTOR (serabelisib + sapanisertib) in Phase 2 for endometrial and breast cancer.
What is Faeth Therapeutics, Inc.'s lead drug candidate?
Faeth Therapeutics, Inc.'s most advanced tracked candidate is piktor (Phase 2) for endometrial and breast cancer.
Who is the CEO of Faeth Therapeutics, Inc.?
Mr. Anand Parikh Esq., J.D. is the chief executive officer of Faeth Therapeutics, Inc. (FTH).
Where is Faeth Therapeutics, Inc. headquartered?
Faeth Therapeutics, Inc. (FTH) is headquartered in Rockville, MD, United States.
What therapeutic areas does Faeth Therapeutics, Inc. focus on?
Faeth Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.